TY - JOUR
T1 - CT-guided transgluteal biopsy for systematic random sampling of the prostate in patients without rectal access
AU - Goenka, Ajit H.
AU - Remer, Erick M.
AU - Veniero, Joseph C.
AU - Thupili, Chakradhar R.
AU - Klein, Eric A.
N1 - Publisher Copyright:
© American Roentgen Ray Society.
PY - 2015/9/1
Y1 - 2015/9/1
N2 - OBJECTIVE. The objective of our study was to review our experience with CT-guided transgluteal prostate biopsy in patients without rectal access. MATERIALS AND METHODS. Twenty-one CT-guided transgluteal prostate biopsy procedures were performed in 16 men (mean age, 68 years; age range, 60-78 years) who were under conscious sedation. The mean prostate-specific antigen (PSA) value was 11.4 ng/mL (range, 2.3-39.4 ng/mL). Six had seven prior unsuccessful transperineal or transurethral biopsies. Biopsy results, complications, sedation time, and radiation dose were recorded. The mean PSA values and number of core specimens were compared between patients with malignant results and patients with nonmalignant results using the Student t test. RESULTS. The average procedural sedation time was 50.6 minutes (range, 15-90 minutes) (n = 20), and the mean effective radiation dose was 8.2 mSv (median, 6.6 mSv; range 3.6-19.3 mSv) (n = 13). Twenty of the 21 (95%) procedures were technically successful. The only complication was a single episode of gross hematuria and penile pain in one patient, which resolved spontaneously. Of 20 successful biopsies, 8 (40%) yielded adenocarcinoma (Gleason score: mean, 8; range, 7-9). Twelve biopsies yielded nonmalignant results (60%): high-grade prostatic intraepithelial neoplasia (n = 3) or benign prostatic tissue with or without inflammation (n = 9). Three patients had carcinoma diagnosed on subsequent biopsies (second biopsy, n = 2 patients; third biopsy, n = 1 patient). A malignant biopsy result was not significantly associated with the number of core specimens (p = 0.3) or the mean PSA value (p = 0.1). CONCLUSION. CT-guided transgluteal prostate biopsy is a safe and reliable technique for the systematic random sampling of the prostate in patients without a rectal access. In patients with initial negative biopsy results, repeat biopsy should be considered if there is a persistent rise in the PSA value.
AB - OBJECTIVE. The objective of our study was to review our experience with CT-guided transgluteal prostate biopsy in patients without rectal access. MATERIALS AND METHODS. Twenty-one CT-guided transgluteal prostate biopsy procedures were performed in 16 men (mean age, 68 years; age range, 60-78 years) who were under conscious sedation. The mean prostate-specific antigen (PSA) value was 11.4 ng/mL (range, 2.3-39.4 ng/mL). Six had seven prior unsuccessful transperineal or transurethral biopsies. Biopsy results, complications, sedation time, and radiation dose were recorded. The mean PSA values and number of core specimens were compared between patients with malignant results and patients with nonmalignant results using the Student t test. RESULTS. The average procedural sedation time was 50.6 minutes (range, 15-90 minutes) (n = 20), and the mean effective radiation dose was 8.2 mSv (median, 6.6 mSv; range 3.6-19.3 mSv) (n = 13). Twenty of the 21 (95%) procedures were technically successful. The only complication was a single episode of gross hematuria and penile pain in one patient, which resolved spontaneously. Of 20 successful biopsies, 8 (40%) yielded adenocarcinoma (Gleason score: mean, 8; range, 7-9). Twelve biopsies yielded nonmalignant results (60%): high-grade prostatic intraepithelial neoplasia (n = 3) or benign prostatic tissue with or without inflammation (n = 9). Three patients had carcinoma diagnosed on subsequent biopsies (second biopsy, n = 2 patients; third biopsy, n = 1 patient). A malignant biopsy result was not significantly associated with the number of core specimens (p = 0.3) or the mean PSA value (p = 0.1). CONCLUSION. CT-guided transgluteal prostate biopsy is a safe and reliable technique for the systematic random sampling of the prostate in patients without a rectal access. In patients with initial negative biopsy results, repeat biopsy should be considered if there is a persistent rise in the PSA value.
KW - CT guidance
KW - Prostate biopsy
KW - Prostate cancer
KW - Prostate-specific antigen (PSA)
UR - http://www.scopus.com/inward/record.url?scp=84942683981&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84942683981&partnerID=8YFLogxK
U2 - 10.2214/AJR.14.14129
DO - 10.2214/AJR.14.14129
M3 - Article
C2 - 26295644
AN - SCOPUS:84942683981
SN - 0361-803X
VL - 205
SP - 578
EP - 583
JO - American Journal of Roentgenology
JF - American Journal of Roentgenology
IS - 3
ER -